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Background: Reducing exposure to toxic environmental agents is a critical area of intervention. Prenatal or
postnatal exposure to certain chemicals has been documented to increase the risk of autism spectrum disorder.
Propionic acid (PA) found in some foods and formed as a metabolic product of gut microbiota has been reported
to mediate the effects of autism. Results from animal studies may help to identify environmental contaminants and
drugs that produce or prevent neurotoxicity, and may thereby aid in the treatment of neurodevelopmental
disorders such as autism. The present study investigated the protective and/or therapeutic effects of vitamin D
against brain intoxication induced by propionic acid (PPA) in rats.
Methods: Twenty-eight young male Western Albino rats were enrolled in the present study. They were grouped into
four equal groups of 7. The control group received only phosphate buffered saline; the oral buffered PPA-treated group
received a neurotoxic dose of 250 mg/kg body weight/day for 3 days; and the Vitamin D-protected group received
1000 IU/kg/day of alpha, 25-dihydroxyvitamin D (3) (1, 25-VD) for two weeks, after which the rats were injected with PPA
250 mg/Kg body weight/day for 3 days. The fourth group received PPA 250 mg/Kg body weight/day for 3 days followed
by alpha, 25-dihydroxyvitamin D (3) (1, 25-VD) for two weeks (Vitamin D therapeutic effect). Vitamin D and calcium were
measured in the plasma of the four studied groups. Serotonin, interferon gamma (IFN-γ), glutathione-s-transferase activity
and DNA double helix breaks were assayed in the brain tissue of the rats for all groups.
Results: The obtained data showed that the PPA-treated group demonstrated higher plasma vitamin D levels compared
to the control rats, together with multiple signs of brain toxicity, as indicated by a depletion of serotonin (5HT), an
increase in IFN-γ and inhibition of glutathione-s-transferase activity as three biomarkers of brain dysfunction. Additionally,
Comet DNA assays showed remarkably higher tail length, tail DNA % damage and tail moment as a neurotoxic effect
of PPA.
Conclusions: Vitamin D showed a greater protective than therapeutic effect on PPA-induced neurotoxicity in rats, as
there was a remarkable amelioration of the impaired biochemically measured parameters representing neurochemical,
inflammation, and detoxification processes.
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Autism spectrum disorder (ASD) is a group of develop-
mental disabilities. Autism is just one disorder on the
spectrum. ASD affects both the brain and body of young
children. These children have atypical development re-
garding their socialization, communication, and behavior
[1]. Despite decades of research, autism remains an idio-
pathic disorder in 90% of cases [1]. The most recent esti-
mate, based on 2008 data from the Centers for Disease
Control surveillance network, reveals that 1 in 88 chil-
dren have autism, reflecting an almost 80% increase
from 2002 data [2]. Despite thousands of studies on the
etiological mechanisms of autism, the pathogenesis of
these disorders remains baffling, apart from a general
belief that they derive from an interaction between se-
veral genes and the environment. Among environmental
factors, only some uncommon viral infections and cer-
tain drugs have been conclusively linked to autism [3].
Epidemiologists suggest that the current epidemic of
autism may be caused by gestational and early childhood
vitamin D deficiency [4]. A hypothesis was proposed by
Cannell [5] that children with vitamin D deficient rickets
have some autistic markers that seem to disappear with
high-dose vitamin D treatment. Moreover, estrogen and
testosterone have very different effects on calcitriol me-
tabolism; these differences may explain the 4:1 male/
female gender ratio in autism. Autism is more frequent
in areas of impaired UVB diffusion and in dark-skinned
persons [6,7]. Additionally, families of higher socioeco-
nomic status [8], as well as with a higher level of educa-
tion [9] are more likely to apply sunscreen to their
children, which explains the numerous studies linking
higher social class with autism.
Of the neurosteroids involved in brain development,
activated vitamin D (calcitriol) is extraordinarily neuro-
protective by inhibiting the production of nitrous oxide,
stimulating neurotropin release, reducing toxic calcium
levels in the brain, reducing inflammatory cytokines
[10], and increasing brain glutathione through its immu-
nomodulating properties [11].
A placebo-controlled study of 20 autistic children over a
period of three months found that multivitamins with
even low doses of vitamin D (150 units or 3.75 mcg) sig-
nificantly improved sleep and gastrointestinal problems
[12-14]. Surprisingly, the Food and Nutrition Board (FNB)
did not increase the recommended dose of vitamin D for
infants, children, or young pregnant women during the
decades in which sun-avoidance was routinely recom-
mended [15]. Where there is inadequate daily sun expo-
sure, oral doses of 1,000-2,000 IU/d are now considered
routine, with much higher doses (up to 50,000 IU) for
rapid repletion being considered safe [16]. Pryor found that
the treatment of one autistic 26 kg boy with 3,000 IU/d of
vitamin D for 3 months resulted in an increase in his25-hydroxy vitamin D level, with concomitant improve-
ments in behavior, learning and IQ scores. (J. Pryor, per-
sonal communication, 2008). Kalueff et al. [17] went even
further, suggesting that vitamin D offers “neuroprotection,
antiepileptic effects, immunomodulation, possible inter-
play with several brain neurotransmitter system and hor-
mones, as well as regulation of behaviours”.
Most recently, Mostafa and Al-Ayadhi [18] reported that
autistic children had significantly lower serum levels of
25-hydroxy vitamin D than healthy children. They proved
that serum 25-hydroxy vitamin D had significantly nega-
tive correlations with scores on the Childhood Autism
Rating Scale. Additionally, increased levels of anti-myelin-
associated glycoprotein (anti-MAG) auto-antibodies were
found in 70% of autistic patients and were negatively
correlated with vitamin D levels. In a recent study by
El-Ansary et al. [19], propionic acid was used to induce
persistent autistic features in rat pups through the alter-
ation of a panel of biomarkers comparable to those re-
ported clinically in autistic patients and in animal models
produced through interventricular infusion of PPA [20,21].
The present study aims to ascertain the protective and
therapeutic effects of vitamin D against propionic acid
(PPA)-induced autistic features in animal models. Se-
rotonin, IFγ, GST (glutathione-S-transferase), and DNA
double strand breaks (Comet assay) were selected as bio-
chemical parameters related to neurotransmission, inflam-
mation, detoxification and DNA damage, respectively.
This could highlight the role of vitamin D in the patho-




A serotonin ELISA kit, a product of Immuno-Biological
Laboratories (IBL, Hamburg, Germany); an IFNγ ELISA
kit, a product of Thermo Scientific (Rockford, IL, USA);
and a glutathione-S-transferase assay kit, a product of
Biovision, USA, were used in the present study. All che-
micals used were of analytical grade and were products
of Sigma-Aldrich, St Louis, MO, USA.
Equipment
An HPLC system, an ELIZA instrument, electrophoresis
equipment, and a Leitz Orthoplan epifluorescence
microscope (magnification 250×) equipped with an exci-
tation filter of 515 to 560 nm and a barrier filter of
590 nm were used in the present study.
Animals
This is an interventional experimental animal study per-
formed on twenty-eight male western albino rats (45–60 g)
(approximately 21 days old). Rats were obtained from
the animal house of the Pharmacy College, King Saud
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temperature, a 12-h dark/light cycle and free access to tap
water and standard laboratory chow. After one week of ac-
climation, the rats were divided into four groups (seven
rats per group). The first group of control animals were fed
with a normal diet during the experimental period; the
second group of PPA-treated rats received 250 mg/Kg
body weight/day for 3 days to induce autistic features; the
third group consisted of the protective group, and received
1000 IU/kg/day of alpha, 25-dihydroxyvitamin D (3) (1, 25-
VD) for two weeks, after which they were treated with PPA
(250 mg/Kg body weight/day for 3 days). The fourth group
received PPA 250 mg/Kg body weight/day for 3 days
followed by alpha, 25-dihydroxyvitamin D (3) (1, 25-VD)
for two weeks (Vitamin D therapeutic effect). PPA and
vitamin D were given orally to rat pups using a gastric
tube. All groups of rats were housed under controlled
temperature conditions (21 ± 1°C) with ad libitum access
to food and water. The rats were weighed daily.
Ethical approval
This work was approved by the Ethics Committee of the
College of Science Research Center of King Saud Uni-




At the end of the feeding trials, the rats were anesthe-
tized with carbon dioxide and decapitated. The brain
was removed from the skull and was dissected into small
pieces and homogenized as a whole in 10 times w/v bi-
distilled water and kept at −80°C until further use for
different biochemical analyses.
Collection of plasma
Plasma was collected from the four investigated groups.
Vitamin D and calcium were analyzed using HPLC at
the facilities of the Prince Mutaib Chair for Biomarkers
of Osteoporosis, King Saud University, Riyadh, KSA.
Assay of serotonin
Serotonin was measured using an ELISA kit from
Immuno-Biological Laboratories (IBL, Hamburg, Germany).
The assay procedure followed the competitive ELISA pro-
tocols, whereby competition takes place between the bio-
tinylated and non-biotinylated antigen for a fixed number
of antibody binding sites. Brain homogenate preparation
(derivatization of serotonin to N-acylserotonin) was part
of the sample dilution. Briefly, serotonin in samples and
controls was acylated with acetic anhydride in acetone
and samples, controls, and standards were applied to
96-well microtiter plates coated with goat anti-rabbit IgG.
Biotinylated serotonin and rabbit antiserum to serotoninwere added to each well and incubated overnight at 4°C.
Para-nitrophenyl-phosphate in a diethanolamine solution
was used as a substrate following the application of alka-
line phosphatase-conjugated goat anti-biotin antibody.
Samples were read at 405 nm on an ELISA plate reader
and quantified using standards supplied by the manu-
facturer. The analytical sensitivity of this product is
0.014 ng/ml.
Assay of IFNγ
IFNγ was measured using an ELISA kit, a product of
Thermo Scientific (Rockford, IL, USA), according to the
manufacturer’s instructions. This assay employs a quan-
titative sandwich enzyme immunoassay technique that
measures IFNγ in less than five hours. In this kit, a poly-
clonal antibody specific to human IFNγ is pre-coated
onto a 96-well microplate with removable strips. IFNγ
in 100 μl standards and samples was sandwiched by
the immobilized antibody and a biotinylated polyclonal
antibody specific to IFNγ, which is recognized by a
streptavidin-peroxidase conjugate. All unbound material
was then washed away and a peroxidase enzyme sub-
strate was added. The color development was stopped
and the intensity of the color was measured at 550 nm
and subtracted from the absorbance at 450 nm. The
minimum level of rat IFNγ detected by this product was
less than 2 pg/ml.
Determination of glutathione-S-transferase activity (GST)
Ten-microliter samples were prepared in a total 50 μl
volume with GST assay buffer, including a negative con-
trol with 50 μl of GST assay buffer only and a positive
control (10 μl of GST positive control diluted 1:50) with
40 μl of GST assay buffer. Five microliters of glutathione
(GSH) was added to each well containing the sample or
control described above. Fifty microliters of 10-times di-
luted CDNB (1-chloro- 2, 4-dinitrobenzene) was mixed
and added to all wells, including the standard. The
GST-catalyzed formation of GS-DNB produces a dini-
trophenyl thioether, which can be detected by a spectro-
photometer at 340 nm.
Comet DNA assay
Brain tissue collected from the rat samples was homoge-
nized in 0.075 M NaCl and 0.024 M ethylenediaminetet-
raacetic acid (EDTA) buffer, pH 7.5, at a ratio of 1 g of
tissue to 1 ml of buffer, and then cooled to 4°C. Volumes
of 6 μl of brain homogenate were suspended in 100 μl
of 0.5% low-melting agarose (LMA) (Sigma-Aldrich,
St Louis, MO, USA) and placed onto microscope slides
that were cleaned and coated with 300 μl of 0.6% normal
melting point (NMP) agarose beforehand. After solidifi-
cation on ice for 10 minutes, the slides were covered
with 0.5% low melting point (LMP) agarose. Once the
Table 1 Plasma levels of Vitamin D (nmol/l) and Ca
(mmol/l) in the four studied groups
Parameters Groups Min. Max. Mean ± S.D. P value
Vit D (nmol/l) Control 52.98 103.56 73.36 ± 16.78 0.001
PPA + D 158.80 289.60 225.50 ± 57.42a
PPA 68.30 117.60 97.28 ± 17.03
D + PPA 128.68 224.40 183.08 ± 34.92a
Ca+2 (mmol/l) Control 2.49 2.69 2.59 ± 0.08 NS
PPA + D 2.33 2.62 2.44 ± 0.09
PPA 2.21 2.55 2.37 ± 0.10
D + PPA 2.30 2.48 2.38 ± 0.06
• Table 1 describes the one-way ANOVA test between the control, P + D, P and
D + P groups in Vit D (nmol/l) and Ca (mmol/l) groups and the Dunnett test for
multiple comparisons.
• Significant differences between the three groups are illustrated as superscript
letters when P <0.05.
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hour in an ice-cold lysis solution, consisting of 100 mM
Na2EDTA, 2.5 M NaCl, 10 mM Tris–HCl, and 1%
sodium sarcosinate, which was adjusted to pH 10 using
1% Triton X-100 and 10% dimethyl sulfoxide (DMSO),
added immediately prior to use. Before electrophoresis,
the slides were removed from the lysing solution and
placed for 20 minutes in a horizontal electrophoresis
unit (near the anode) that was filled with an alkaline buf-
fer to allow the unwinding of the DNA and to express
alkali-labile damage. The electrophoresis alkaline solu-
tion consisted of 1 mM Na2EDTA and 300 mM NaOH,
pH 13. After the unwinding of the DNA, electrophoresis
was carried out in the freshly prepared alkaline solution
for 20 minutes at 25 V (300 mA). Electrophoresis at a
high pH resulted in structures resembling comets, as ob-
served by fluorescence microscopy; the intensity of the
comet tail relative to the head reflected the number of
DNA breaks. Afterwards, the slides were neutralized by
adding Tris buffer (pH 7.5), stained with 30 ml of
ethidium bromide (Sigma-Aldrich, St Louis, MO, USA)
(20 mg/L), and then covered and stored in sealed boxes
at 4°C for further analysis.
All preparation steps were performed under dimmed
light to prevent additional DNA damage. Images of 100
randomly selected cells (50 counts on each duplicate slide)
were analyzed for each sample. For each group, a total of
500 cells were analyzed under a Leitz Orthoplan epifluo-
rescence microscope (magnification 250×) equipped with
an excitation filter of 515 to 560 nm and a barrier filter of
590 nm. The microscope was connected through a camera
to a computer-based image analysis system (Comet Assay
IV software, Perspective Instruments).
Comets were randomly captured at a constant depth
of the gel, avoiding the edges of the gel, occasional dead
cells, and superimposed comets. DNA damage was mea-
sured as tail length (TL = distance of DNA migration
from the center of the body of the nuclear core) and
DNA tail intensity (TI = % of genomic DNA that mi-
grated during the electrophoresis from the nuclear core
to the tail). By presenting all three parameters together,
more information could be obtained on the extent of the
DNA damage.
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences (SPSS, Chicago, IL, USA). The results
were expressed as the mean ± standard error of the mean
(SEM). All statistical comparisons between the control
and PA-treated rat groups were performed using the one-
way analysis of variance (ANOVA) test complemented
with the Dunnett test for multiple comparisons. Sig-
nificance was assigned at the level of P <0.05. Re-
ceiver operating characteristics curve (ROC) analysis wasperformed. Area under the curve (AUC), cut-off values,
and degree of specificity and sensitivity were calculated.
Pearson correlations were calculated.
Results
Data are presented in Tables 1, 2, and 3 together with
Figures 1, 2, 3, 4, and 5. Table 1 lists the plasma levels of
vitamin D and calcium presented as the mean ± S.D for
the four studied groups. It can be easily noticed that
vitamin D was higher in the PPA-treated group compared
to the control and, as expected, was remarkably and sig-
nificantly elevated in the protected and therapeutically
treated groups compared either to the control or PPA-
treated groups. In contrast, calcium shows non-significant
variation between the four studied groups. Figure 1 pre-
sents the percentage change of vitamin D and calcium in
the treated groups relative to the control (presented as
100%). It can be easily observed that a 33%, 207% and
150% increase in vitamin D levels was recorded for
PPA-treated, vitamin D- protected and vitamin D-treated
groups, respectively. Figure 1 also demonstrates the non-
significant change in calcium levels.
Table 2 and Figure 2 demonstrate a significant im-
pairment in the production of serotonin, IFγ and GST
induced by PPA, together with the protective and res-
torative effects of vitamin D. Vitamin D shows more
protective than therapeutic effects, but there was still
a significant difference when compared to the control
group. This is shown graphically in Figure 2 as a lower %
change compared to the control than that seen after PPA-
treatment.
Table 3 and Figure 3 demonstrate PPA-induced DNA
damage in the brains of treated rats. The evidence for
DNA damage is the significant increase in the comet pa-
rameters, presented as tail length (μm), tail DNA (%)
and tail moment (arbitrary units). Table 3 also demon-
strates the potency of vitamin D in protecting against
Table 2 Serotonin (ng/100 mg), IFγ (Pg/100 mg) and GST (μmol/min/100 mg) groups
Parameters Groups Min. Max. Percent change Mean ± S.D. P value
Serotonin (ng/100 mg) Control 3.41 4.80 100.00 4.12 ± 0.51 0.001
PPA 2.32 3.03 66.86 2.76 ± 0.29a
VIT D(P) 3.25 3.45 80.97 3.34 ± 0.07a
VIT D(T) 2.52 3.06 68.41 2.82 ± 0.22a
IFγ (Pg/100 mg) Control 88.27 115.64 100.00 99.91 ± 8.84 0.001
PPA 177.34 194.59 184.88 184.72 ± 6.24a
VIT D(P) 152.05 160.01 156.62 156.49 ± 2.95a
VIT D(T) 165.48 181.05 172.84 172.68 ± 5.28a
GST (μmol/min/100 mg) Control 0.78 0.95 100.00 0.85 ± 0.06 0.001
PPA 0.44 0.55 59.00 0.50 ± 0.04a
VIT D(P) 0.65 0.75 82.77 0.70 ± 0.04a
VIT D(T) 0.59 0.66 72.35 0.61 ± 0.02a
• Table 2 describes the One-way ANOVA test between the control, PPA and vitamin D (P&T) groups in serotonin (ng/100 mg), IFγ (Pg/100 mg) and GST (μmol/min/
100 mg) groups and the Dunnett test for multiple comparisons.
• Significant differences between the three groups are illustrated as superscript letters when P <0.05.
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the DNA-damaging effects of PPA. This amelioration
was observed as a significant decrease in PPA-induced
DNA damage. ROC analysis showed satisfactory values
of area under the curve, sensitivity and specificity.
Discussion
Nutritional factors play an important role in promoting
good health, and a preponderance of evidence has linked
nutritional deficiencies to an exacerbation of cognitive de-
terioration. Recently, vitamin D has come under investiga-
tion for its role in cognitive preservation. While a role forTable 3 Tail Length (μm), Tail DNA% and Tail Moments (Units
Parameters Groups Min. Max.
Tail Length (μm) Control 1.06 1.42
PPA 4.67 5.34
VIT D(P) 2.97 3.66
VIT D(T) 3.96 4.52
Tail DNA% Control 1.22 1.62
PPA 4.51 5.15
VIT D(P) 3.11 3.41
VIT D(T) 3.82 4.34
Tail Moments (Units) Control 1.42 2.15
PPA 21.96 25.78
VIT D(P) 9.91 11.84
VIT D(T) 15.12 18.51
• Table 3 describes the one-way ANOVA test between the control, PPA and OMEGA
the Dunnett test for multiple comparisons.
• Significant differences between the three groups are illustrated as superscript lettvitamin D in tissue growth and bone metabolism is well
established, the presence of the vitamin D receptor and
enzymes involved in the hydroxylation of vitamin D
(25-OHase and 1,a-OHase) in the brain implies a role for
this hormone in cognitive function and dementia [22-24].
Circulating 1,25(OH)2D enters cells by passive diffu-
sion and binds to a nuclear vitamin D receptor (VDR),
causing a conformational change that allows the VDR to
dimerize with the retinoid X receptor [25]. VDRs and/or
1α-hydroxylase have been identified in a wide range of
cells, including brain cells. While the importance of
vitamin D levels for normal bone formation, parathyroid) groups
Percent change Mean ± S.D. P value
100.00 1.25 ± 0.16 0.001
396.92 4.96 ± 0.28a
262.73 3.28 ± 0.33a
339.37 4.24 ± 0.23a
100.00 1.40 ± 0.17 0.001
347.44 4.85 ± 0.27a
232.49 3.25 ± 0.12a
291.35 4.07 ± 0.23a
100.00 1.76 ± 0.37 0.001
1370.59 24.07 ± 1.87a
605.97 10.64 ± 0.87a
983.37 17.27 ± 1.49a
groups in Tail Length (μm), Tail DNA% and Tail Moments (Units) groups and
ers when P <0.05.
Figure 1 Percentage change in vitamin D and calcium in the
plasma of the PPA, protected (PPA + D), and therapeutic
(D + PPA) groups compared to the control.
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cumented, the levels needed for optimal brain develop-
ment and function are unknown [26-29].
Table 1 demonstrates a higher level of vitamin D in the
plasma of PPA-treated rats compared to the control. Be-
cause the neurotoxicity of both intraventricularly and
orally administered PPA was recently ascertained [19,20],
higher plasmatic vitamin D could reflect a lower brain
concentration, which could be due to an abnormally low
number of VDRs in the brain of PPA-treated rats. While
some studies reported no observed impairments in wor-
king memory or anxiety in the VDR-KO model mouse
[30], others showed anxiety-like behavior and behavioral
impairment [31,32].
Table 2 demonstrates that vitamin D shows more pro-
tective than therapeutic effects against PPA neurotoxicity.
The remarkable protective effects of vitamin D against
PPA’s negative effect on serotonin levels reported in the
present study are in concurrence with the previous work
of Cass et al. [33], which reported that calcitriol was ef-
fective in protecting against methamphetamine (METH)-Figure 2 Percentage change in serotonin, IFγ and GST in the three treinduced reductions in striatal and nucleus accumbens
levels of dopamine and serotonin (5HT) in male rats.
Moreover, the suggested lower number of VDRs as a
neurotoxic feature of PPA could be supported by consid-
ering the protective effect of vitamin D via upregulation of
VDR mRNA 12–24 hr after brief glutamate exposure in
cultured neurons. This could suggest that vitamin D3 may
play a role in mechanisms relevant to protection against
PPA neurotoxicity through up-regulation of VDR expres-
sion in the brains of treated rats.
Regarding the anti-inflammatory effect of vitamin D, it
can easily be observed from Table 2 that vitamin D
could lower the percentage increase in IFN-γ from 85%
in PPA-treated unprotected rats to 57% in the vitamin
D-protected group. In contrast, vitamin D shows a very
low therapeutic potency. These results could confirm
the anti-inflammatory effects of vitamin D through the
suppression of pro-inflammatory cytokines and the in-
hibition of NF-κB signaling [10].
The remarkable inhibition of GST reported in the
present study could easily be related to the oxidative ef-
fect of PPA previously reported as increased lipid pero-
xides, depleted glutathione and less active glutathione
peroxidase [19].
Previous studies have shown that vitamin D could pro-
tect the structure and integrity of neurons through detoxi-
fication mechanisms and neurotrophin synthesis [34-38].
Similar to the benefits of traditional antioxidant nutrients,
1,25(OH)2D3 inhibits inducible nitric oxide synthase
(iNOS) [39], an enzyme that is upregulated during ische-
mic events and in patients with Alzheimer’s, Parkinson’s
disease and autism [40]. 1, 25(OH) 2D3 also enhances in-
nate antioxidant pathways, upregulates gamma glutamyl
transpeptidase [41] and subsequently increases gluta-
thione. Glutathione is an innate antioxidant that protects
oligodendrocytes and the integrity of the nerve conduc-
tion pathway critical to mental processing. These earlierated groups compared to the control.
Figure 3 Percentage change in tail length, tail DNA% and tail moment in the three treated groups compared to the control.
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vitamin D attenuates the oxidative effect of PPA and en-
hances the detoxification mechanism through the activa-
tion of GST.
Table 3 and Figure 4 show the remarkable DNA double
strand breaks with PPA, together with the potent protec-
tive and mild therapeutic effects of vitamin D supplemen-
tation. Vitamin D given before oral administration of PPA
was effective at ameliorating its neurotoxic effect. Tail
length was reduced from 4.95 μm to 3.28 μm (i.e., from a
397 to a 263% increase compared to the control), and %
DNA damage was reduced to 3.25 compared to a value of
4.85 in PPA-treated rats. The most remarkable protective
effect of vitamin D was clearly seen in tail moment, which
was reduced to a value of 10.64 compared to 24.07 in
PPA-treated rats (reduction in the % increase value from
1371% to 606% in vitamin-D-protected rats). In contrast,
the therapeutic effect of vitamin D supplementation was
remarkably less compared to its protective effect. The
DNA damaging effect reported in the present study could
be easily related to the previously suggested loss of VDRs
with PPA treatment. This is because the elevation in
the levels of 8-hydroxy-2-deoxyguanosine (8-OHdG), a
marker of oxidative DNA damage, corresponded to a
complete loss of VDR expression [42].
Because VDR expression is dependent on 1,25OHD
availability, its loss was taken to suggest a possible role for
1,25OHD in protecting cells against hyper-proliferationFigure 4 Photograph showing comet tailing in the PPA-treated group
vitamin D (III &IV) in rat brains, compared to control (I).and oxidative DNA damage [43]. Vitamin D-treated rats
have shown a significant reduction in damage due to oxi-
dative stress and a corresponding increase in bone density
[44]. Further evidence to support the potential for vitamin
D to resolve oxidative damage may be found in a rando-
mized clinical trial in patients with colorectal adenoma
where a 25% reduction in 8-OHdG following vitamin D
supplementation was reported [45]. Lipid peroxidation is
another marker for oxidative damage and is indicated by
the formation of malondialdehyde, which plays an im-
portant role in carcinogenesis [46]. Treatment of rats with
calcitriol increased the expression of VDR and greatly re-
duced levels of malondialdehyde, further supporting the
role of high levels of calcitriol in protecting DNA against
oxidative damage. All these studies could be used to
support our suggestion of VDR loss as a PPA-oxidative-
stress-related neurotoxicity event, and of the protective
effect of vitamin D supplementation against the etiology
of autistic features recently reported as a persistent neuro-
toxic effect of PPA.
ROC analysis shows satisfactory values for area under
the curve, sensitivity and specificity. This could confirm
that the measured parameters could be used as bio-
markers to study either PPA neurotoxicity or vitamin D
protective and/or therapeutic effects. These suggestions
could be supported through the positive and negative
correlations shown in Figure 4 (A-G), which help to sug-
gest the possibility of using vitamin D supplementation(II) together with the protective and therapeutic effects of
Figure 5 Comet assay performed. (A-G): Pearson correlations between plasmatic levels of vitamin D, calcium and different measured
brain parameters.
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autistic features after birth.
Conclusion
Based on the anti-inflammatory, antioxidant, and DNA re-
pair actions of vitamin D reported in the present study,
vitamin D could be used as a supplement in patients with
autism to ameliorate the symptoms related to these path-
ways. As maternal vitamin D deficiency may predispose
children to autism, a high consumption of vitamin D-rich
seafood, and an avoidance of the use of sunblock during
pregnancy could be suggested as an autism prevention
strategy.
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